Skip to Content

Generic Bevespi Aerosphere Availability

Bevespi Aerosphere is a brand name of formoterol/glycopyrrolate, approved by the FDA in the following formulation(s):

BEVESPI AEROSPHERE (formoterol fumarate; glycopyrrolate - aerosol, metered;inhalation)

  • Manufacturer: PEARL THERAPS INC
    Approval date: April 25, 2016
    Strength(s): 0.0048MG/INH;0.0090MG/INH [RLD]

Has a generic version of Bevespi Aerosphere been approved?

No. There is currently no therapeutically equivalent version of Bevespi Aerosphere available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Bevespi Aerosphere. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Compositions, methods and systems for respiratory delivery of two or more active agents
    Patent 8,324,266
    Issued: December 4, 2012
    Inventor(s): Vehring; Reinhard & Hartman; Michael Steven & Lechuga-Ballesteros; David & Smith; Adrian Edward & Joshi; Vidya B. & Dwivedi; Sarvajna Kumar
    Assignee(s): Pearl Therapeutics, Inc.
    Compositions, methods and systems are provided for pulmonary or nasal delivery of two or more active agents via a metered dose inhaler. In one embodiment, the compositions include a suspension medium, active agent particles, and suspending particles, in which the active agent particles and suspending particles form a co-suspension within the suspension medium.
    Patent expiration dates:
    • May 28, 2030
      ✓ 
      Patent use: USE IN THE LONG-TERM, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
  • Compositions, methods and propellant-based systems for respiratory delivery of glycopyrrolate and one or more active agents
    Patent 8,703,806
    Issued: April 22, 2014
    Assignee(s): Pearl Therapeutics, Inc.
    Compositions, methods and systems are provided for pulmonary or nasal delivery of two or more active agents via a metered dose inhaler. In one embodiment, the compositions include a suspension medium, active agent particles, and suspending particles, in which the active agent particles and suspending particles form a co-suspension within the suspension medium.
    Patent expiration dates:
    • May 28, 2030
      ✓ 
      Patent use: USE IN THE LONG-TERM, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
  • Compositions for pulmonary delivery of long-acting β2 adrenergic receptor agonists and associated methods and systems
    Patent 8,808,713
    Issued: August 19, 2014
    Assignee(s): Pearl Thereapeutics, Inc.
    Compositions, methods and systems are provided for pulmonary delivery of long-acting muscarinic antagonists and long-acting β2 adrenergic receptor agonists via a metered dose inhaler. In particular embodiments, the compositions include a suspension medium, active agent particles, and suspending particles, in which the active agent particles and suspending particles form a co-suspension within the suspension medium.
    Patent expiration dates:
    • May 28, 2030
      ✓ 
      Patent use: USE IN THE LONG-TERM, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
      ✓ 
      Drug product
  • Compositions, methods and systems for respiratory delivery of two or more active agents
    Patent 8,815,258
    Issued: August 26, 2014
    Assignee(s): Pearl Therapeutics, Inc.
    Compositions, methods and systems are provided for pulmonary or nasal delivery of two or more active agents via a metered dose inhaler. In one embodiment, the compositions include a suspension medium, active agent particles, and suspending particles, in which the active agent particles and suspending particles form a co-suspension within the suspension medium.
    Patent expiration dates:
    • March 17, 2031
      ✓ 
      Patent use: USE IN THE LONG-TERM, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
  • Compositions, methods and systems for respiratory delivery of two or more active agents
    Patent 9,415,009
    Issued: August 16, 2016
    Assignee(s): Pearl Therapeutics, Inc.
    Compositions, methods and systems are provided for pulmonary or nasal delivery of two or more active agents via a metered dose inhaler. In one embodiment, the compositions include a suspension medium, active agent particles, and suspending particles, in which the active agent particles and suspending particles form a co-suspension within the suspension medium.
    Patent expiration dates:
    • May 28, 2030
      ✓ 
      Patent use: USE IN THE LONG-TERM, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
  • Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems
    Patent 9,463,161
    Issued: October 11, 2016
    Assignee(s): Pearl Therapeutics, Inc.
    Compositions, methods and systems are provided for pulmonary delivery of long-acting muscarinic antagonists and long-acting β2 adrenergic receptor agonists via a metered dose inhaler. In particular embodiments, the compositions include a suspension medium, active agent particles, and suspending particles, in which the active agent particles and suspending particles form a co-suspension within the suspension medium.
    Patent expiration dates:
    • May 28, 2030
      ✓ 
      Patent use: USE IN THE LONG-TERM, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
      ✓ 
      Drug product

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • April 25, 2019 - NEW PRODUCT

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide